Global biodefense market is big target for Triangle firm Heat Biologics
“This is an important step in realizing our vision to develop and commercialize new biopharmaceuticals and vaccines for the global biodefense market,” Jeff Wolf, chief executive officer of Heat, says in announcing the company’s latest deal – an acquisition. .
Read More
